相关实验视频

Updated: May 30, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

在现实世界实践环境中治疗急性缺血性中风的苏赫祥药片 (SUNRISE):多中心注册表的协议

Xinxing Lai^1,2, Xuejiao Xiong³, Qi Jia¹

¹Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

BMC complementary medicine and therapies

|January 28, 2025

概括

"日出"研究调查了在现实环境下治疗急性缺血性中风 (AIS) 的苏赫祥 (SHX) 药丸. 这项研究旨在澄清SHX药丸的含义.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

苏赫祥 (SHX) 药丸是急性缺血性中风 (AIS) 的常见治疗方法.
以前的研究表明,SHX药丸对AIS患者有好处,但实际有效性尚不清楚.
在AIS中需要长期,真实世界的SHX药丸在AIS中的有效性和安全性的数据.

研究的目的:

评估Suhexiang (SHX) 药丸在急性缺血性中风 (AIS) 患者的实际临床实践环境中的有效性和安全性.
为患者的特征提供见解,这些患者可能从SHX治疗中受益.
在AIS管理中支持SHX药片的个性化治疗决策.

主要方法:

在现实世界实践环境中治疗急性缺血性中风的苏赫祥药丸 (SUNRISE) 是一项多中心,前性,观察性研究.
将包括在发病7天内接受SHX药片治疗的1000名AIS患者.
主要结局是中风后3个月实现独立的患者比例 (mRS得分0-2).

主要成果:

数据收集正在进行中;初步结果正在等待.
这项研究将提供关于SHX药片有效性和安全性概况的真实数据.
分析将重点关注三个月后的功能独立性.

结论:

太阳升起注册结果将阐明SHX药在常规AIS护理中的作用.
结果将为AIS患者提供个性化的SHX药片治疗策略.
这项研究为中风管理提供了有价值的现实世界的证据.

关键词:

急性缺血性中风是一次急性缺血性中风.现实世界的真实世界.登记处登记处登记处登记处苏赫祥的药丸是一种药丸.传统的中国医学是传统的中国医学.

更多相关视频

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Published on: January 15, 2017

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...